Appeals Court Revives Regeneron’s Antitrust Lawsuit Against Novartis Over Vision Treatment
The 2nd US Circuit Court of Appeals in Manhattan has breathed new life into an antitrust lawsuit brought by Regeneron Pharmaceuticals against Novartis. The lawsuit centers around prescription treatments aimed at addressing a condition that can result in severe eye disorders, potentially leading to permanent blindness.
The decision, rendered on Monday, marked a pivotal moment in the ongoing legal battle between the pharmaceutical giants. The appeals court ruled that a lower court judge had erred in dismissing Regeneron’s lawsuit, citing the incorrect application of legal standards to the claims put forth by the plaintiff.
The dispute between Regeneron and Novartis underscores the high stakes involved in the development and commercialization of treatments for critical medical conditions. At the heart of the lawsuit are allegations of anticompetitive behavior by Novartis, aimed at stifling competition and maintaining a dominant position in the market for prescription therapies targeting the identified eye disorder.
Read more: Paris Appeals Court Overturns Novartis, Roche $475M Antitrust Fine
The precise nature of the alleged antitrust violations has not been fully disclosed, but Regeneron’s contentions suggest a concerted effort by Novartis to undermine competition and impede the market entry of rival treatments. Such tactics, if proven, could have far-reaching implications for the pharmaceutical industry, particularly in the realm of specialized medications addressing complex medical needs.
Source: Reuters
Featured News
Big Tech Braces for Potential Changes Under a Second Trump Presidency
Nov 6, 2024 by
CPI
Trump’s Potential Shift in US Antitrust Policy Raises Questions for Big Tech and Mergers
Nov 6, 2024 by
CPI
EU Set to Fine Apple in First Major Enforcement of Digital Markets Act
Nov 5, 2024 by
CPI
Six Indicted in Federal Bid-Rigging Schemes Involving Government IT Contracts
Nov 5, 2024 by
CPI
Ireland Secures First €3 Billion Apple Tax Payment, Boosting Exchequer Funds
Nov 5, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Remedies Revisited
Oct 30, 2024 by
CPI
Fixing the Fix: Updating Policy on Merger Remedies
Oct 30, 2024 by
CPI
Methodology Matters: The 2017 FTC Remedies Study
Oct 30, 2024 by
CPI
U.S. v. AT&T: Five Lessons for Vertical Merger Enforcement
Oct 30, 2024 by
CPI
The Search for Antitrust Remedies in Tech Leads Beyond Antitrust
Oct 30, 2024 by
CPI